| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CPLX1 |
| Uniprot No | O14810 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-134aa |
| 氨基酸序列 | MEFVMKQALG GATKDMGKML GGDEEKDPDA AKKEEERQEA LRQAEEERKA KYAKMEAERE AVRQGIRDKY GIKKKEEREA EAQAAMEANS EGSLTRPKKA IPPGCGDEVE EEDESILDTV IKYLPGPLQD MLKK |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CPLX1重组蛋白的3篇代表性文献示例(注：内容基于领域内常见研究方向模拟，建议通过学术数据库核实具体文献)：
---
1. **文献名称**：*"Complexin-1重组蛋白在突触囊泡融合中的调控机制研究*
**作者**：Wei, Y., et al.
**摘要**：本研究通过大肠杆菌系统表达并纯化了人源CPLX1重组蛋白，体外实验表明其通过结合SNARE复合体抑制囊泡自发融合，但在动作电位触发时解除抑制，促进神经递质释放。
2. **文献名称**：*"Structural basis of complexin-1 function in synaptic exocytosis"*
**作者**：Chen, X., et al.
**摘要**：利用重组CPLX1蛋白的晶体结构分析，揭示了其N端结构域与SNARE复合体的相互作用模式，阐明了其在调节囊泡融合精度中的分子机制。
3. **文献名称**：*"Complexin-1 knockout rescues synaptic dysfunction in a Parkinson’s disease model"*
**作者**：Li, H., et al.
**摘要**：构建CPLX1重组蛋白体外补充实验，证明其在帕金森病模型中可逆转α-突触核蛋白过度聚集导致的突触传递异常，提示潜在治疗价值。
---
**提示**：实际文献检索建议使用关键词"Complexin-1 recombinant protein"或"CPLX1 expression"在PubMed、Web of Science等平台筛选，重点关注蛋白功能、结构解析或疾病关联研究。
**Background of CPLX1 Recombinant Protein**
CPLX1 (Complexin-1) is a synaptic vesicle-associated protein critical for regulating neurotransmitter release. It belongs to the complexin family, which includes CPLX1. CPLX2. CPLX3. and CPLX4. with CPLX1 and CPLX2 being predominantly expressed in the brain. Structurally, CPLX1 contains an N-terminal domain, a central α-helix, and a C-terminal domain, enabling its interaction with the SNARE (soluble NSF attachment protein receptor) complex—a core machinery mediating synaptic vesicle fusion.
Functionally, CPLX1 acts as a dual regulator: it stabilizes the primed SNARE complex to prevent spontaneous fusion while simultaneously enhancing synchronous neurotransmitter release upon calcium influx. This delicate balance is vital for precise synaptic transmission. Dysregulation of CPLX1 has been implicated in neurological disorders such as schizophrenia, epilepsy, and autism spectrum disorders, highlighting its clinical relevance.
Recombinant CPLX1 protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells*) to study its structure-function relationships *in vitro*. Purification tags (e.g., His-tag) are often incorporated to facilitate isolation. The recombinant protein serves as a tool to investigate synaptic mechanisms, screen potential neuroactive compounds, and model pathological mutations linked to neuropsychiatric conditions. Its application extends to structural studies (e.g., X-ray crystallography) and functional assays (e.g., liposome fusion experiments), providing insights into synaptic plasticity and neuropharmacology.
Research on CPLX1 recombinant protein continues to advance our understanding of synaptic dysregulation and may contribute to therapeutic strategies for neurological diseases.
×
